| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor, Angiotensin, Type 2 | 29 | 2023 | 39 | 12.140 |
Why?
|
| Kidney | 17 | 2024 | 1353 | 2.650 |
Why?
|
| Blood Pressure | 13 | 2021 | 1350 | 2.300 |
Why?
|
| Receptors, G-Protein-Coupled | 6 | 2025 | 292 | 2.290 |
Why?
|
| Receptor, Angiotensin, Type 1 | 15 | 2023 | 60 | 2.270 |
Why?
|
| Kidney Tubules, Proximal | 16 | 2017 | 108 | 2.200 |
Why?
|
| Renin-Angiotensin System | 6 | 2022 | 102 | 2.150 |
Why?
|
| Obesity | 16 | 2023 | 2279 | 1.880 |
Why?
|
| Hypertension | 10 | 2021 | 1316 | 1.830 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 8 | 2017 | 55 | 1.660 |
Why?
|
| Acute Kidney Injury | 4 | 2023 | 634 | 1.650 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2020 | 551 | 1.520 |
Why?
|
| Rats, Zucker | 17 | 2023 | 41 | 1.520 |
Why?
|
| Proteinuria | 3 | 2023 | 106 | 1.510 |
Why?
|
| Natriuresis | 8 | 2017 | 37 | 1.510 |
Why?
|
| Nitric Oxide | 5 | 2020 | 446 | 1.440 |
Why?
|
| Lipopolysaccharides | 3 | 2023 | 293 | 1.430 |
Why?
|
| Rats | 42 | 2023 | 3693 | 1.370 |
Why?
|
| Angiotensin I | 3 | 2020 | 10 | 1.350 |
Why?
|
| Sodium Chloride, Dietary | 4 | 2023 | 38 | 1.240 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 15 | 2007 | 100 | 1.200 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2023 | 285 | 1.190 |
Why?
|
| Peptide Fragments | 4 | 2020 | 779 | 1.120 |
Why?
|
| Kidney Diseases | 3 | 2024 | 481 | 1.080 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-2 | 2 | 2024 | 14 | 1.070 |
Why?
|
| Oligopeptides | 6 | 2013 | 117 | 1.020 |
Why?
|
| Adiposity | 2 | 2019 | 191 | 1.010 |
Why?
|
| Inflammation | 4 | 2020 | 1428 | 0.960 |
Why?
|
| Angiotensin II | 7 | 2020 | 163 | 0.920 |
Why?
|
| Animals | 57 | 2025 | 34195 | 0.830 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2022 | 26 | 0.810 |
Why?
|
| Interleukin-10 | 2 | 2014 | 173 | 0.810 |
Why?
|
| Podocytes | 1 | 2022 | 73 | 0.780 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2021 | 61 | 0.730 |
Why?
|
| Thiophenes | 1 | 2021 | 60 | 0.710 |
Why?
|
| Reperfusion Injury | 1 | 2021 | 103 | 0.690 |
Why?
|
| Receptors, Angiotensin | 3 | 2005 | 21 | 0.680 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2016 | 54 | 0.670 |
Why?
|
| Oxidative Stress | 3 | 2016 | 807 | 0.660 |
Why?
|
| CD11b Antigen | 1 | 2019 | 37 | 0.640 |
Why?
|
| Diet, High-Fat | 3 | 2016 | 214 | 0.630 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 219 | 0.630 |
Why?
|
| Sulfonamides | 1 | 2021 | 264 | 0.630 |
Why?
|
| Receptors, Dopamine D1 | 8 | 2011 | 85 | 0.620 |
Why?
|
| Signal Transduction | 8 | 2021 | 4543 | 0.620 |
Why?
|
| Kidney Cortex | 3 | 2013 | 20 | 0.600 |
Why?
|
| Solute Carrier Family 12, Member 3 | 1 | 2018 | 4 | 0.600 |
Why?
|
| Thinness | 2 | 2011 | 70 | 0.600 |
Why?
|
| Hyperinsulinism | 5 | 2015 | 68 | 0.590 |
Why?
|
| Lipid Metabolism | 2 | 2019 | 359 | 0.580 |
Why?
|
| Cell Line | 8 | 2020 | 2770 | 0.540 |
Why?
|
| Monocytes | 1 | 2019 | 354 | 0.540 |
Why?
|
| Vasoconstrictor Agents | 4 | 2017 | 136 | 0.530 |
Why?
|
| Macrophages | 2 | 2023 | 618 | 0.510 |
Why?
|
| Angiotensins | 3 | 2023 | 8 | 0.480 |
Why?
|
| Cyclic GMP | 4 | 2010 | 94 | 0.460 |
Why?
|
| Insulin | 7 | 2019 | 1210 | 0.450 |
Why?
|
| Sodium | 6 | 2018 | 295 | 0.440 |
Why?
|
| Renin | 4 | 2016 | 94 | 0.430 |
Why?
|
| Tetrazoles | 3 | 2014 | 68 | 0.430 |
Why?
|
| Up-Regulation | 3 | 2013 | 867 | 0.420 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2021 | 1231 | 0.410 |
Why?
|
| Benzimidazoles | 3 | 2014 | 134 | 0.410 |
Why?
|
| Kidney Glomerulus | 2 | 2023 | 78 | 0.400 |
Why?
|
| Estrogens | 1 | 2015 | 515 | 0.400 |
Why?
|
| Imidazoles | 5 | 2017 | 194 | 0.370 |
Why?
|
| Pyridines | 5 | 2017 | 230 | 0.360 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 4356 | 0.360 |
Why?
|
| Sex Characteristics | 1 | 2013 | 319 | 0.360 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2007 | 137 | 0.360 |
Why?
|
| Acetophenones | 1 | 2010 | 12 | 0.350 |
Why?
|
| Liver | 5 | 2015 | 1764 | 0.350 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2010 | 15 | 0.350 |
Why?
|
| Antihypertensive Agents | 2 | 2013 | 411 | 0.350 |
Why?
|
| Weight Gain | 1 | 2013 | 405 | 0.340 |
Why?
|
| Mice, Inbred C57BL | 5 | 2023 | 4429 | 0.330 |
Why?
|
| NADPH Oxidases | 1 | 2010 | 116 | 0.330 |
Why?
|
| Streptozocin | 2 | 2007 | 24 | 0.320 |
Why?
|
| Triglycerides | 3 | 2019 | 573 | 0.320 |
Why?
|
| Male | 40 | 2019 | 61314 | 0.310 |
Why?
|
| Dopamine | 6 | 2003 | 286 | 0.300 |
Why?
|
| Diuresis | 2 | 2005 | 58 | 0.300 |
Why?
|
| Angiotensin II Type 2 Receptor Blockers | 3 | 2017 | 4 | 0.290 |
Why?
|
| beta-Adrenergic Receptor Kinases | 1 | 2007 | 26 | 0.280 |
Why?
|
| Glycogen | 1 | 2007 | 63 | 0.280 |
Why?
|
| Receptor, Insulin | 1 | 2007 | 67 | 0.280 |
Why?
|
| Vasoconstriction | 1 | 2006 | 102 | 0.260 |
Why?
|
| Ligands | 3 | 2022 | 536 | 0.260 |
Why?
|
| Body Weight | 3 | 2019 | 1005 | 0.260 |
Why?
|
| Kidney Tubules | 2 | 2003 | 82 | 0.260 |
Why?
|
| Biphenyl Compounds | 3 | 2014 | 57 | 0.260 |
Why?
|
| Glucose | 2 | 2010 | 885 | 0.260 |
Why?
|
| Glomerular Filtration Rate | 4 | 2013 | 503 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2020 | 1692 | 0.260 |
Why?
|
| Hypoglycemic Agents | 4 | 2007 | 443 | 0.260 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2006 | 237 | 0.240 |
Why?
|
| Mice | 8 | 2025 | 17747 | 0.240 |
Why?
|
| DNA Polymerase III | 1 | 2025 | 27 | 0.240 |
Why?
|
| Cytokines | 2 | 2021 | 1290 | 0.230 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2025 | 154 | 0.230 |
Why?
|
| Energy Intake | 2 | 2019 | 493 | 0.220 |
Why?
|
| Humans | 19 | 2025 | 124822 | 0.220 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2023 | 58 | 0.210 |
Why?
|
| Receptors, Dopamine | 1 | 2003 | 40 | 0.210 |
Why?
|
| Cathepsin L | 1 | 2022 | 11 | 0.210 |
Why?
|
| Carcinogenesis | 1 | 2025 | 333 | 0.190 |
Why?
|
| Superoxide Dismutase | 4 | 2011 | 138 | 0.190 |
Why?
|
| Pharmacological Phenomena | 1 | 2021 | 1 | 0.190 |
Why?
|
| Clostridium Infections | 1 | 2025 | 245 | 0.190 |
Why?
|
| Receptor, ErbB-2 | 1 | 2025 | 514 | 0.190 |
Why?
|
| Doxorubicin | 1 | 2022 | 298 | 0.180 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2016 | 219 | 0.180 |
Why?
|
| Drug Synergism | 1 | 2020 | 230 | 0.170 |
Why?
|
| Microbiota | 1 | 2025 | 391 | 0.170 |
Why?
|
| Lipid Peroxides | 4 | 1987 | 15 | 0.170 |
Why?
|
| Uncoupling Protein 1 | 1 | 2019 | 29 | 0.160 |
Why?
|
| RNA, Small Interfering | 3 | 2017 | 670 | 0.160 |
Why?
|
| THP-1 Cells | 1 | 2019 | 21 | 0.160 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2020 | 101 | 0.160 |
Why?
|
| Cell Size | 1 | 2019 | 80 | 0.160 |
Why?
|
| Epididymis | 1 | 2019 | 54 | 0.160 |
Why?
|
| Body Temperature | 1 | 2019 | 115 | 0.160 |
Why?
|
| Adipose Tissue, Brown | 1 | 2019 | 82 | 0.160 |
Why?
|
| Adiponectin | 1 | 2019 | 117 | 0.160 |
Why?
|
| Cyclic AMP | 4 | 2006 | 250 | 0.160 |
Why?
|
| Adipose Tissue, White | 1 | 2019 | 79 | 0.160 |
Why?
|
| Adipocytes | 1 | 2019 | 159 | 0.150 |
Why?
|
| Potassium | 2 | 2018 | 280 | 0.150 |
Why?
|
| Dimerization | 1 | 2018 | 144 | 0.150 |
Why?
|
| Mice, Knockout | 3 | 2016 | 3753 | 0.150 |
Why?
|
| Phosphorylation | 7 | 2007 | 1626 | 0.150 |
Why?
|
| Cadmium | 6 | 1989 | 29 | 0.150 |
Why?
|
| Receptors, Dopamine D2 | 3 | 2002 | 45 | 0.150 |
Why?
|
| Methylamines | 1 | 2017 | 18 | 0.140 |
Why?
|
| Random Allocation | 3 | 2016 | 437 | 0.140 |
Why?
|
| Time Factors | 3 | 2021 | 6312 | 0.140 |
Why?
|
| Enzyme Inhibitors | 6 | 2006 | 582 | 0.140 |
Why?
|
| Blood Pressure Determination | 1 | 2018 | 106 | 0.140 |
Why?
|
| GTP-Binding Proteins | 4 | 2007 | 177 | 0.140 |
Why?
|
| Fatty Acids | 1 | 2019 | 351 | 0.140 |
Why?
|
| Biogenic Amines | 2 | 1987 | 19 | 0.140 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2017 | 113 | 0.130 |
Why?
|
| Homeostasis | 2 | 2011 | 692 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 682 | 0.130 |
Why?
|
| Metals | 3 | 1985 | 61 | 0.130 |
Why?
|
| Nitrates | 2 | 2006 | 28 | 0.130 |
Why?
|
| Systole | 1 | 2016 | 198 | 0.130 |
Why?
|
| Nitrites | 2 | 2006 | 46 | 0.130 |
Why?
|
| Diet | 1 | 2023 | 1138 | 0.130 |
Why?
|
| Inflammasomes | 1 | 2017 | 150 | 0.130 |
Why?
|
| Cadmium Poisoning | 2 | 1985 | 3 | 0.120 |
Why?
|
| Chromatography, Liquid | 1 | 2016 | 195 | 0.120 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 230 | 0.120 |
Why?
|
| Sodium, Dietary | 1 | 2015 | 35 | 0.120 |
Why?
|
| In Vitro Techniques | 7 | 2006 | 973 | 0.120 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 331 | 0.120 |
Why?
|
| Reference Values | 1 | 2016 | 713 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 151 | 0.110 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 130 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2025 | 2427 | 0.110 |
Why?
|
| Protein Kinase C | 3 | 2003 | 150 | 0.110 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 143 | 0.110 |
Why?
|
| Sodium-Hydrogen Exchangers | 2 | 2005 | 40 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2016 | 1017 | 0.110 |
Why?
|
| Epithelial Cells | 3 | 2010 | 910 | 0.110 |
Why?
|
| Gene Deletion | 1 | 2016 | 795 | 0.100 |
Why?
|
| Gonads | 1 | 2013 | 36 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2003 | 212 | 0.100 |
Why?
|
| Triiodothyronine | 1 | 2013 | 64 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2025 | 2513 | 0.100 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2013 | 137 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1425 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 1691 | 0.100 |
Why?
|
| Glucose Tolerance Test | 1 | 2013 | 209 | 0.100 |
Why?
|
| Organ Size | 1 | 2013 | 435 | 0.100 |
Why?
|
| G-Protein-Coupled Receptor Kinases | 1 | 2011 | 5 | 0.100 |
Why?
|
| Gene Expression | 2 | 2007 | 1569 | 0.090 |
Why?
|
| Jejunum | 2 | 2002 | 129 | 0.090 |
Why?
|
| Phenotype | 1 | 2021 | 4260 | 0.090 |
Why?
|
| Diabetic Nephropathies | 2 | 2010 | 107 | 0.090 |
Why?
|
| Aging | 3 | 2003 | 1189 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 824 | 0.090 |
Why?
|
| Lead | 3 | 1987 | 23 | 0.090 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 4 | 2003 | 39 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2002 | 207 | 0.090 |
Why?
|
| Blotting, Western | 1 | 2013 | 1110 | 0.090 |
Why?
|
| Dopamine Agonists | 4 | 2003 | 79 | 0.090 |
Why?
|
| Estradiol | 1 | 2013 | 535 | 0.090 |
Why?
|
| Synaptosomes | 2 | 1987 | 31 | 0.080 |
Why?
|
| Receptors, Immunologic | 1 | 2010 | 113 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2017 | 1527 | 0.080 |
Why?
|
| Adipose Tissue | 1 | 2013 | 472 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 727 | 0.080 |
Why?
|
| Cell Membrane | 3 | 2007 | 463 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2006 | 2825 | 0.080 |
Why?
|
| Endothelial Cells | 2 | 2017 | 527 | 0.080 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 354 | 0.080 |
Why?
|
| Brain Chemistry | 2 | 1988 | 124 | 0.080 |
Why?
|
| Antioxidants | 1 | 2011 | 336 | 0.070 |
Why?
|
| Opossums | 2 | 2005 | 12 | 0.070 |
Why?
|
| Manganese Poisoning | 1 | 1987 | 3 | 0.070 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2007 | 15 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1291 | 0.070 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 338 | 0.070 |
Why?
|
| Corpus Striatum | 1 | 1987 | 91 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2007 | 701 | 0.070 |
Why?
|
| Biomarkers | 1 | 2016 | 3063 | 0.070 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2007 | 64 | 0.070 |
Why?
|
| Feeding Behavior | 1 | 2013 | 712 | 0.070 |
Why?
|
| Potassium Chloride | 1 | 2006 | 53 | 0.070 |
Why?
|
| Cytosol | 1 | 2007 | 161 | 0.070 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2006 | 59 | 0.070 |
Why?
|
| Nitroprusside | 1 | 2006 | 46 | 0.070 |
Why?
|
| Endothelin-1 | 1 | 2006 | 40 | 0.070 |
Why?
|
| Losartan | 1 | 2006 | 35 | 0.070 |
Why?
|
| Acetylcholine | 1 | 2006 | 84 | 0.070 |
Why?
|
| Protein Transport | 1 | 2007 | 369 | 0.060 |
Why?
|
| Urination | 1 | 2005 | 23 | 0.060 |
Why?
|
| Purine Nucleosides | 1 | 2025 | 9 | 0.060 |
Why?
|
| Vasodilator Agents | 1 | 2006 | 205 | 0.060 |
Why?
|
| Laminin | 1 | 2025 | 70 | 0.060 |
Why?
|
| Mice, Nude | 1 | 2025 | 711 | 0.050 |
Why?
|
| Second Messenger Systems | 1 | 2003 | 12 | 0.050 |
Why?
|
| Type C Phospholipases | 1 | 2003 | 28 | 0.050 |
Why?
|
| Colforsin | 1 | 2003 | 50 | 0.050 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2003 | 28 | 0.050 |
Why?
|
| Phospholipases A | 1 | 2003 | 39 | 0.050 |
Why?
|
| Adenylyl Cyclases | 1 | 2003 | 83 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2003 | 75 | 0.050 |
Why?
|
| Binding Sites | 2 | 2022 | 1297 | 0.050 |
Why?
|
| Phylogeny | 1 | 2025 | 697 | 0.050 |
Why?
|
| Macrolides | 1 | 2002 | 29 | 0.050 |
Why?
|
| Brain | 5 | 1989 | 3010 | 0.050 |
Why?
|
| Hypertension, Renal | 1 | 2002 | 38 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2003 | 159 | 0.050 |
Why?
|
| Thiazoles | 1 | 2002 | 97 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2002 | 81 | 0.050 |
Why?
|
| Rats, Inbred F344 | 4 | 2003 | 105 | 0.050 |
Why?
|
| Aorta, Thoracic | 1 | 2006 | 528 | 0.050 |
Why?
|
| Female | 4 | 2025 | 66580 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2025 | 791 | 0.050 |
Why?
|
| Sodium Chloride | 1 | 2001 | 92 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2005 | 850 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 113 | 0.050 |
Why?
|
| Mitosis | 1 | 2001 | 237 | 0.040 |
Why?
|
| Adenosine | 2 | 1998 | 128 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2025 | 887 | 0.040 |
Why?
|
| Peptides | 1 | 2022 | 794 | 0.040 |
Why?
|
| Benzazepines | 3 | 2003 | 65 | 0.040 |
Why?
|
| Dopamine Antagonists | 3 | 2003 | 50 | 0.040 |
Why?
|
| Superior Cervical Ganglion | 1 | 1998 | 15 | 0.040 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2017 | 9 | 0.040 |
Why?
|
| Caspase Inhibitors | 1 | 2017 | 31 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2025 | 3342 | 0.040 |
Why?
|
| Caspase 1 | 1 | 2017 | 43 | 0.040 |
Why?
|
| Permeability | 1 | 2017 | 119 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 162 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 2017 | 150 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2017 | 329 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2017 | 3061 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 504 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 1998 | 350 | 0.030 |
Why?
|
| Blood Glucose | 3 | 2004 | 1142 | 0.030 |
Why?
|
| Testis | 2 | 1989 | 412 | 0.030 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1994 | 10 | 0.030 |
Why?
|
| Nucleosides | 1 | 1994 | 17 | 0.030 |
Why?
|
| Adenine Nucleotides | 1 | 1994 | 41 | 0.030 |
Why?
|
| Sulfhydryl Compounds | 1 | 1994 | 53 | 0.030 |
Why?
|
| Bromocriptine | 2 | 2002 | 6 | 0.030 |
Why?
|
| Genistein | 2 | 2002 | 39 | 0.020 |
Why?
|
| Aromatic-L-Amino-Acid Decarboxylases | 2 | 2002 | 17 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2002 | 96 | 0.020 |
Why?
|
| Levodopa | 2 | 2002 | 91 | 0.020 |
Why?
|
| Flavonoids | 2 | 2002 | 78 | 0.020 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2010 | 30 | 0.020 |
Why?
|
| Superoxides | 1 | 2010 | 154 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 128 | 0.020 |
Why?
|
| Binding, Competitive | 2 | 2002 | 186 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 1989 | 31 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 2002 | 626 | 0.020 |
Why?
|
| Lipofuscin | 1 | 1988 | 1 | 0.020 |
Why?
|
| Catalase | 1 | 1989 | 50 | 0.020 |
Why?
|
| Pigments, Biological | 1 | 1988 | 7 | 0.020 |
Why?
|
| Vitamin E | 1 | 1988 | 66 | 0.020 |
Why?
|
| Manganese | 2 | 1985 | 48 | 0.020 |
Why?
|
| Malondialdehyde | 1 | 1987 | 35 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 1987 | 98 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1987 | 254 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 1987 | 443 | 0.020 |
Why?
|
| Tritium | 2 | 2002 | 173 | 0.020 |
Why?
|
| Nitrophenols | 1 | 1985 | 15 | 0.020 |
Why?
|
| Manganese Compounds | 1 | 1985 | 9 | 0.020 |
Why?
|
| Organophosphorus Compounds | 1 | 1985 | 23 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1985 | 234 | 0.010 |
Why?
|
| Chlorides | 1 | 1985 | 106 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1984 | 176 | 0.010 |
Why?
|
| Protein Kinase C-delta | 1 | 2003 | 17 | 0.010 |
Why?
|
| Protein Kinase C beta | 1 | 2003 | 21 | 0.010 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2003 | 29 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 2003 | 154 | 0.010 |
Why?
|
| Monoamine Oxidase | 1 | 2002 | 11 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2002 | 152 | 0.010 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2002 | 25 | 0.010 |
Why?
|
| Bucladesine | 1 | 2002 | 20 | 0.010 |
Why?
|
| Vanadates | 1 | 2002 | 12 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 2002 | 65 | 0.010 |
Why?
|
| Domperidone | 1 | 2002 | 6 | 0.010 |
Why?
|
| Tyrosine | 1 | 2002 | 152 | 0.010 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2001 | 8 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2002 | 229 | 0.010 |
Why?
|
| Thymidine | 1 | 2001 | 54 | 0.010 |
Why?
|
| Serine | 1 | 2002 | 173 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2001 | 39 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2001 | 85 | 0.010 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 2001 | 8 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2001 | 412 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2002 | 224 | 0.010 |
Why?
|
| Adenylyl Cyclase Inhibitors | 1 | 1998 | 11 | 0.010 |
Why?
|
| Ganglionic Blockers | 1 | 1998 | 13 | 0.010 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 1998 | 22 | 0.010 |
Why?
|
| Vasopressins | 1 | 1998 | 43 | 0.010 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 1998 | 52 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1998 | 94 | 0.010 |
Why?
|
| Age Factors | 1 | 2002 | 2820 | 0.010 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 1994 | 3 | 0.010 |
Why?
|
| Neostriatum | 1 | 1994 | 11 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 1994 | 25 | 0.010 |
Why?
|
| Phenethylamines | 1 | 1994 | 14 | 0.010 |
Why?
|
| Xanthines | 1 | 1994 | 14 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 1994 | 360 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 1994 | 457 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1989 | 142 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1987 | 138 | 0.000 |
Why?
|
| 4-Nitrophenylphosphatase | 1 | 1985 | 3 | 0.000 |
Why?
|
| Substrate Specificity | 1 | 1985 | 291 | 0.000 |
Why?
|
| Temperature | 1 | 1985 | 305 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1985 | 426 | 0.000 |
Why?
|
| Kinetics | 1 | 1985 | 1325 | 0.000 |
Why?
|
| Hippocampus | 1 | 1987 | 830 | 0.000 |
Why?
|